Bronnen:
Spelman T, et al. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. ECTRIMS 2018, abstract 59.
Spelman T, et al. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. ECTRIMS 2018, abstract 59.